Analyzing...
Loading company...
Intelligence analysis not yet available for this company.
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹922 Cr revenue.
COGS 59.0%, employees 9.4%.
“All future economic benefits including the double digit royalties from Advance in Europe will now accrue directly to us.”
“we hope to share concrete progress on one or more new licensing arrangements in the coming quarters.”
“We are hopeful to sign a potential deal in the next twelve months.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | - | - |
| ROCE | - | - |
| Net Margin | - | - |
| EBITDA Margin | - | - |
| Debt To Equity | - | - |
| Current Ratio | - | - |
| Rev Growth 3yr | - | - |
| EPS Growth 3yr | - | - |
| Asset Turnover | - | - |
| (₹ Cr) | FY2025 | FY2025 | FY2024 | FY2024 | FY2023 | FY2023 | FY2022 |
|---|---|---|---|---|---|---|---|
| Other Income | ₹32 Cr 0.0% | ₹32 Cr +5.1% | ₹30 Cr 0.0% | ₹30 Cr +56.4% | ₹19 Cr 0.0% | ₹19 Cr +115.8% | ₹9 Cr |
| Total Income | ₹954 Cr 0.0% | ₹954 Cr +12.3% | ₹850 Cr 0.0% | ₹850 Cr +24.0% | ₹685 Cr 0.0% | ₹685 Cr +21.1% | ₹566 Cr |
| COGS | ₹544 Cr 0.0% | ₹544 Cr +12.3% | ₹484 Cr 0.0% | ₹484 Cr +26.0% | ₹385 Cr 0.0% | ₹385 Cr +22.5% | ₹314 Cr |
| ₹847 Cr 0.0% | ₹847 Cr +11.8% | ₹758 Cr 0.0% | ₹758 Cr +13.3% | ₹669 Cr 0.0% | ₹669 Cr +8.2% | ₹619 Cr | |
| Profit Before Tax | ₹106 Cr 0.0% | ₹106 Cr +16.3% | ₹92 Cr 0.0% | ₹92 Cr +65.7% | ₹55 Cr 0.0% | ₹55 Cr ↑ Recovery | (₹53 Cr) |
| Net Profit | ₹106 Cr 0.0% | ₹106 Cr +12.4% | ₹95 Cr 0.0% | ₹95 Cr +74.9% | ₹54 Cr 0.0% | ₹54 Cr ↑ Recovery | (₹5 Cr) |
| Other Comprehensive Income | (₹0.75 Cr) 0.0% | (₹0.75 Cr) -122.8% | (₹0.34 Cr) 0.0% | (₹0.34 Cr) -88.6% | (₹0.18 Cr) 0.0% | (₹0.18 Cr) ↓ Decline | ₹1 Cr |
| EPS | ₹20.99 | ₹20.99 | ₹18.68 | ₹18.68 | ₹13.28 | ₹13.28 | (₹1.18) |
| Diluted Shares | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Orchid Pharma Limited has informed the Exchange about Transcript
Orchid Pharma Limited has informed the Exchange about Link of Recording
Monitoring Agency Report for the Quarter-III ended on December 31, 2025
Orchid Pharma Limited has informed the Exchange about Presentation
Orchid Pharma Limited has informed the Exchange regarding outcome of the Board meeting held on February 11, 2026.
Orchid Pharma Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
Orchid Pharma Limited has informed the Exchange about Schedule of meet
Orchid Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Orchid Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Orchid Pharma Limited has informed the Exchange about Transcript
Monitoring Agency Report for the Quarter-II of F.Y. 2025-26, ended on September 30, 2025- Qrchid Pharma Limited
Orchid Pharma Limited has informed the Exchange about Link of Recording
Orchid Pharma Limited has informed the Exchange about Investor Presentation
Orchid Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
Orchid Pharma Limited has informed the Exchange about Schedule of investors meet
No dividend history available for this company.